Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib 150 mg vs 300 mg in current smokers with advanced NSCLC (second-line)
CTR20140101Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Dec 2014; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20140101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140101.